Awaiting development: Guidance and quality standards

Showing 101 to 110 of 283

Guidance and quality standards awaiting development
Title	Type
Elinzanetant for Vasomotor symptoms [ID6544]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]	Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]	Technology appraisal guidance